Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.40 |
| ▸ | CDK9 | P50750 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925070 | 0.93 | EGFR (0.53) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL18202224 | 0.93 | EGFR (0.52) | EGFRMKNK2CCNT1CDK9 | |
| SCHEMBL19921246 | 0.93 | EGFR (0.50) | EGFRMKNK2CCNT1CDK9 | |
| SCHEMBL18202235 | 0.92 | EGFR (0.49) | EGFRMKNK2CCNT1CDK9 | |
| SCHEMBL18229877 | 0.92 | EGFR (0.52) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL18202177 | 0.89 | EGFR (0.46) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL18202145 | 0.88 | EGFR (0.51) | EGFRMKNK2CCNT1CDK9 | |
| SCHEMBL18202359 | 0.88 | EGFR (0.45) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL18202334 | 0.87 | EGFR (0.73) | EGFR | |
| SCHEMBL18239605 | 0.86 | EGFR (0.59) | EGFRMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-12-13 | — | — | US | disclosed |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3312179-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-25 | — | — | EP | disclosed |
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
| EP-3290419-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016173438-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | 南京明德新药研发股份有限公司 | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 199/4885MKNK1 219/4885 |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 199/4885MKNK1 219/4885 |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 199/4885MKNK1 219/4885 |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885MKNK2 90/4885MKNK1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.